Clover Health Investments, Corp. filings document the company’s Medicare Advantage insurance business, physician enablement technology, operating results, governance, and material events. Recent 8-K reports furnish earnings releases, guidance updates, Medicare Advantage enrollment information, Regulation FD presentations, and supplemental shareholder Q&A materials related to financial performance and business priorities.
Proxy materials cover annual meeting matters, board and governance disclosures, executive compensation, equity awards, and related stockholder voting items. Other current reports document officer transitions, principal financial and accounting officer appointments, compensatory arrangements, and formal disclosures connected to the company’s remote-first corporate structure and public-company reporting obligations.
Clover Health Investments, Corp. (CLOV) Chief Accounting Officer Joseph Frank Oldakowski received an award covering 186,403 shares of Class A common stock on November 4, 2026. Twenty-five percent of the restricted stock units will vest on the first anniversary of that date, with the remaining units vesting in 12 equal quarterly installments beginning three months later. Vesting is subject to continued service on each vesting date, and the award will be fully vested on November 4, 2030. His direct position following the transaction was 462,300 shares.
Clover Health Investments, Corp. (CLOV) Chief Financial Officer Joseph Clay Thornton received a time-based restricted stock unit award covering 328,947 shares of Class A common stock on November 4, 2026. His reported direct position following the transaction was 1,573,882 shares. Twenty-five percent of the RSUs vest on the first anniversary of November 4, 2026; the rest vest in 12 equal quarterly installments beginning three months after that anniversary, subject to continued service on each vesting date. The RSUs will be fully vested on November 4, 2030.
Clover Health Investments, Corp. reported third-quarter revenue of $759.3 million, up 52.9% from $496.7 million a year earlier, primarily reflecting Medicare Advantage membership growth and higher per-member premiums. Net income was $6.4 million, compared with a $24.4 million loss. For the nine months ended September 30, 2026, revenue was $2.252 billion, up 57%, and net income was $61.8 million, versus a $36.2 million loss.
Nine-month Adjusted EBITDA, a non-GAAP measure, was $97.2 million, compared with $45.0 million; operating cash flow was $203.5 million, compared with $1.2 million. Cash, cash equivalents and investments totaled $512.6 million at September 30, 2026. Adjusted SG&A was 15.3% of revenue, compared with 16.5% in the prior-year period.
At September 30, 2026, Clover operated Medicare Advantage plans in five states and 203 counties, with 158,907 members. Average membership for the nine-month period was 156,610, compared with 105,228 in 2025.
Clover Health Investments, Corp. (CLOV) reported third-quarter revenue of $759.3 million, up 52.9% year over year, and GAAP net income of $6.435 million, versus a $24.377 million loss a year earlier. Average Medicare Advantage membership was 158,383, up 46.3%; consolidated gross profit was $129.8 million, up 77.3%, and Adjusted EBITDA was $16.1 million, up $14 million year over year.
The company raised 2026 guidance to $2.97–$3.00 billion in revenue, $25–$35 million in GAAP net income, $540–$555 million in consolidated gross profit, $75–$85 million in Adjusted EBITDA, and 157,000–158,000 average Medicare Advantage members.
Effective November 4, 2026, Joseph Clay Thornton became CFO and Joseph Frank Oldakowski became Chief Accounting Officer. Their annual salaries are $450,000 and $410,000, respectively; cash incentive targets are up to 75% of Thornton’s base salary and 50% of Oldakowski’s eligible earnings. Their promotional RSU grants, subject to approval, have stated grant-date fair values of $1.5 million for Thornton and $850,000 for Oldakowski.
Clover Health Investments, Corp. (CLOV) Chief Legal Officer Karen Soares sold 19,275 shares of Class A Common Stock on October 20, 2026, at a weighted average price of $4.66 per share. The sale was made under a Rule 10b5-1 plan adopted March 13, 2026. Soares directly held 1,573,423 shares after the sale.
Clover Health Investments, Corp. (CLOV) officer Jamie L. Reynoso, CEO, Medicare Advantage, sold 4,066 Class A Common Stock shares on October 19, 2026, at a weighted average price of $4.41 per share. The shares were sold in multiple transactions at prices ranging from $4.32 to $4.54 under a Rule 10b5-1 trading plan adopted March 12, 2026. Reynoso held 2,770,351 shares directly after the sale.
Clover Health Investments, Corp. officer Karen Soares gave notice of a proposed sale of 19,275 common shares, with an aggregate market value of $85,581.00. The shares were acquired upon the vesting of restricted stock units during the period September 15 through October 15, 2026. The notice also lists two sales by Soares during the preceding three months.
Clover Health Investments, Corp. (CLOV) Chief Executive Officer Andrew Toy sold 62,176 Class A common shares on October 15, 2026, at a weighted average price of $4.68 per share. The shares were sold in a required sell-to-cover transaction to fund tax withholding tied to quarterly vesting of 6.25% of restricted stock units originally granted October 15, 2024. The sale was not discretionary and was made under a Rule 10b5-1 plan. Toy held 9,078,334 shares after the sale.
Clover Health Investments, Corp. officer Jamie Reynoso reported a proposed sale of 4,066 common shares, with an aggregate market value of $18,215.68, through Morgan Stanley Smith Barney LLC for an approximate sale date of October 19, 2026. His sales history for the prior three months lists 18,273 shares on October 15, 2,006 on October 7, 8,750 on October 5, 1,921 on September 17 and 9,273 on September 15, 2026.
Clover Health Investments, Corp. (CLOV) Chief Legal Officer Karen Soares sold 14,673 Class A shares on October 15, 2026, at a weighted average of $4.68 per share pursuant to a Rule 10b5-1 plan. The mandated sell-to-cover transaction funded tax withholding tied to quarterly vesting of 6.25% of restricted stock units granted October 15, 2024; the sale was not discretionary. She directly held 1,592,698 shares afterward.